No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Medical - Instruments & Supplies
Sansure Biotech Inc., founded in Changsha, China, in 2008, is dedicated to the global development and commercialization of advanced diagnostic and research products. The company offers a diverse range of solutions, including upstream nucleic acid extraction kits, real-time PCR systems for both clinical and investigative purposes, and fluorescence detection platforms. Their extensive product portfolio encompasses diagnostic assays for critical conditions like the novel coronavirus, viral hepatitis, and AIDS. Furthermore, they provide blood screening and general extraction kits, tests for cancer-related biomarkers, and solutions for respiratory, sexually transmitted, digestive tract, prenatal, postnatal, and genetic diseases. Sansure Biotech also supplies essential laboratory instrumentation and various consumables, primarily serving hospitals and scientific laboratories worldwide.
www.sansure.com.cnNo one on the platform currently holds 688289.SS.
No tracked institution reports a position in 688289.SS as of their last filing.
No one on the platform has traded 688289.SS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 4.4% | 26.0% | — | — | — | |
| Rev. Growth % | 12.6% | -19.2% | ||||
| Profit Margin % | 12.1% | 29.4% | ||||
| Free Cash Flow Margin % | -10.9% | 1.8% | ||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.7B | +3.5% | $0.41 | $0.38–$0.46 | — | 3 |
| 2027 | $1.9B | +9.8% | $0.45 | $0.42–$0.48 | — | 3 |
| 2028 | $2.1B | +9.2% | $0.48 | $0.48–$0.48 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 688289.SSSansure Biotech Inc. | $15.53 | +0.06% | $9.0B | — |
| 002626.SZXiamen Kingdomway Group Company | $16.23 | +0.56% | $9.9B | — |
| 300171.SZTofflon Science and Technology Group Co., Ltd. | $13.66 | -0.65% | $10.4B | — |
| 300294.SZChina Resources Boya Bio-pharmaceutical Group Co., Ltd. | $13.92 | -0.14% | $7.0B | — |
| 300595.SZAutek China Inc. |
| $9.85 |
| -0.51% |
| $8.8B |
| — |
| 301207.SZHualan Biological Bacterin Inc. | $18.05 | +0.84% | $10.7B | — |
| 600993.SSMayinglong Pharmaceutical Group Co., Ltd. | $22.21 | -0.54% | $9.6B | — |
Source: Financial Modeling Prep · peers by sector/industry